Trial Profile
An Open Label Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura (ITP)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2021
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Idiopathic thrombocytopenic purpura; Thrombocytopenia
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Amgen
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 25 Jun 2017 Results (data cut off 24 feb 2016, n=65) of over 6 year follow up, presented at the 22nd Congress of the European Haematology Association